"Analgesics in the Netherlands" is now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Mon Dec 07 2015


Dutch consumers became more price conscious when it comes to medicines over the course of the review period and they were numerous reasons for this. First of all, adverse economic conditions in the Netherlands have led consumers to spend less money as their disposable income levels have declined. Second, health insurance costs have increased for Dutch consumers for several years in a row. Third, the number of medicines covered by health insurance has declined in recent years. And finally, the prices charged for medicines in chemists/pharmacies has became more transparent as consumers have become more aware of the extra costs they have to pay when buying medicines in chemists/pharmacies which are not covered by their health insurance. The increased price consciousness of Dutch consumers has led to a shift away from prescription medicines towards OTC products in general. Analgesics was the OTC category most influenced by this trend towards the end of the review period as parapharmacies/drugstores and various other retail channels offered an increasingly wide range of analgesics and consumers were more confident about self-medicating with analgesics.

Full Report Details at
- http://www.fastmr.com/prod/1082095_analgesics_netherlands.aspx?afid=302

Competitive Landscape

Bayer Consumer Care BV remained the leading player in analgesics in value terms in 2015, although its value sales declined in 2015 as well as over the entire review period. Bayer is present in all analgesic categories, with the exception of diclofenac. The company’s flagship brands include Finimal, which is present in both adult acetaminophen and paediatric acetaminophen, Aspirine, which is present in aspirin, and Aleve, which is present in naproxen. Bayer’s value share in analgesics is in decline because of the underperformance of most of the company’s brands, which were under pressure due to the growing shares of private label in analgesics. Another reason for the declining value share of Bayer towards the end of the review period was the withdrawal of Kinder Finimal from the category.

Industry Prospects

Analgesics is expected to underperform over the forecast period, declining in value at a CAGR of -1% at constant 2015 prices. The category is set to suffer from the anticipated underperformance of acetaminophen and aspirin. Acetaminophen is the largest analgesics category and the expected decline in the growth rate of these products is set to have a major impact on overall sales of analgesics. Sales of acetaminophen are expected to decline over the forecast period due to maturity of the category and the increasing numbers of consumers who are opting for stronger analgesics.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Netherlands with research from Euromonitor's team of in-country analysts.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Analgesics in South Korea
- Analgesics in Tunisia
- Analgesics in the United Arab Emirates
- Analgesics in Mexico
- Analgesics in Algeria

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »